ETF Inflow Update: IVW, AXP, BSX, PGR
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 29 2025
0mins
Source: NASDAQ.COM
Stock Performance Overview
- 52-Week Range: IVW's stock has a low point of $79.31 and a high point of $116.39 over the past year, with the most recent trade recorded at $114.79.
- Technical Analysis: The comparison of the current share price to the 200-day moving average is highlighted as a useful technique for investors.
Exchange-Traded Funds (ETFs) Insights
- Trading Mechanism: ETFs function similarly to stocks, where investors buy and sell "units" instead of shares. These units can be created or destroyed based on investor demand.
- Monitoring Changes: Weekly tracking of changes in shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (old units destroyed), which can influence the underlying assets of the ETFs.
Additional Information
- Author's Perspective: The views expressed in the article are solely those of the author and do not necessarily represent the opinions of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 47.170
Low
94.00
Averages
108.14
High
132.00
Current: 47.170
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology and vascular therapies (ICVT), watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Adobe and Others Hit Annual Lows Amid Analyst Downgrades
- Adobe Stock Decline: Adobe (ADBE) shares fell to $196.90 during intraday trading on Friday, marking an eight-year low primarily due to concerns over AI competition and the departure of its CFO, despite reporting Q2 revenue of $6.62 billion, a 13% year-over-year increase, exceeding expectations.
- Analyst Downgrades Impact: Freedom Broker analyst downgraded Adobe from ‘Buy’ to ‘Hold’ and slashed the price target by over 50% to $250, citing a shift in growth quality and management's trade-off of near-term subscription revenue for customer acquisition, indicating weakened market confidence in Adobe's future.
- Chewy Faces Challenges: Chewy (CHWY) shares slid to a fresh 52-week low of $18.22 on Friday; despite reporting revenue and earnings growth in Q1, management warned of a challenging consumer pet environment, prompting analysts to cut price targets, with Goldman Sachs lowering it to $34 while maintaining a ‘Buy’ rating.
- Boston Scientific Stock Drop: Boston Scientific (BSX) shares fell to an annual low of $45.99 on Friday after receiving multiple price target cuts, with Piper Sandler lowering its target to $65, highlighting challenges from deceleration in key drivers and a more conservative outlook for 2027 growth estimates.
See More
Boston Scientific Stock Price Decline Analysis
- Poor Stock Performance: Boston Scientific (BSX) shares have fallen over 50% year-to-date, reflecting market disappointment with its growth expectations, particularly as management has repeatedly lowered guidance, undermining investor confidence.
- Guidance Downgrade: The management has revised its 2026 organic revenue growth forecast down to between 6.5% and 8%, and has indicated flat revenue growth for Q2 and Q3, raising concerns about the company's long-term investment appeal amid declining procedure usage.
- Analyst Optimism: Despite the bearish market sentiment, 27 out of 31 analysts still rate the stock as a buy, with a consensus price target of $78 per share, indicating a potential upside of 65%, which reflects analysts' confidence in the company's recovery potential.
- Valuation Challenges: Boston Scientific currently trades at a mid-teen forward valuation, comparable to other medical device firms like Abbott and Medtronic, and achieving a premium valuation will likely require a faster-than-expected recovery in growth, which appears challenging in the current market environment.
See More
Boston Scientific Shares Plunge Over 50% Amid Guidance Cuts
- Significant Stock Decline: Boston Scientific (NYSE: BSX) shares have plummeted over 50% year-to-date, primarily due to the company's ongoing downward revisions of its full-year 2026 guidance, which has severely undermined investor confidence and elicited a negative market response.
- Performance Guidance Adjustments: Management initially projected organic sales growth of 10% to 11% in February, but after reporting a 19.5% growth for 2025, investor reactions were poor, leading to further reductions in April and May, with 2026 organic revenue guidance now set between 6.5% and 8%.
- Analyst Sentiment Remains Positive: Despite the bearish market sentiment, 27 out of 31 analysts covering the stock still rate it as a buy, with a consensus price target of $78 per share, indicating a potential upside of 65%, reflecting analysts' confidence in the company's recovery prospects.
- Valuation Challenges Ahead: Boston Scientific currently trades at a forward valuation in the mid-teens, comparable to other medical device firms like Abbott and Medtronic, and achieving a premium valuation will likely require a faster-than-expected recovery in growth, which remains uncertain pending upcoming Q2 results and guidance.
See More
Boston Scientific Stock Decline Analysis
- Guidance Downgrade: Boston Scientific has lowered its organic revenue growth forecast for 2026 from 10%-11% to 6.5%-8%, resulting in a more than 50% decline in stock price this year, reflecting market pessimism about its future growth prospects.
- Analyst Rating Discrepancy: Despite a bearish shift in analyst sentiment, 27 out of 31 analysts still rate the stock as a buy, indicating optimism about potential recovery, with a consensus price target of $78 per share representing a 65% upside.
- Market Reaction Lag: Concerns over declining usage of the Watchman heart implant suggest that revenue may remain flat in Q2 and Q3, making it challenging for the stock to recover in the short term, prompting investors to proceed with caution.
- Cautious Investment Advice: While the attractive price target for Boston Scientific may entice investors, its current valuation aligns with other medical device companies, necessitating a careful assessment of potential risks versus rewards before making investment decisions.
See More
SpaceX Sets Record with $75 Billion IPO, Aiming for 25-30% Opening Pop
- Historic IPO: SpaceX is conducting a record-breaking IPO today, raising up to $75 billion, with expectations of a 25-30% opening pop, which could attract short-term investors and potentially destabilize the company's shareholder base.
- Market Reaction: Oil prices have dropped over 3% to below $85 per barrel due to optimism surrounding a potential peace deal between the U.S. and Iran, indicating market sentiment ahead of next week's G7 Summit.
- Executive Changes: Adobe announced that CFO Dan Durn is leaving to join Marvell; despite beating earnings expectations, Adobe's stock fell 7%, reflecting market concerns about slowing growth.
- Analyst Rating Changes: Citi upgraded AMD from hold to buy, anticipating that Meta will significantly increase its purchases of AMD chips, indicating AMD's strengthening position in the graphics processing unit market as a legitimate competitor to Nvidia.
See More
Elfun Trusts Q1 2026 Investment Moves Revealed
- Portfolio Adjustment: Elfun Trusts exited three stocks in Q1 2026, notably selling all 707,792 shares of Abbott Laboratories, which impacted the portfolio by -1.97%, indicating a cautious stance towards the healthcare sector.
- New Stock Additions: The fund added 1,148,700 shares of Boston Scientific, valued at approximately $72.08 million, representing 1.75% of the portfolio, reflecting optimism in the medical device industry.
- Key Position Increases: Elfun Trusts increased its stake in S&P Global by 47,560 shares, bringing total holdings to 222,549 shares, a 27.18% increase, demonstrating confidence in financial information services.
- Reduction Strategy: The fund reduced positions in 18 stocks, notably cutting 169,600 shares of Emerson Electric, a 25.49% decrease, reflecting a reassessment of the industry's outlook.
See More
Adobe and Others Hit Annual Lows Amid Analyst Downgrades
- Adobe Stock Decline: Adobe (ADBE) shares fell to $196.90 during intraday trading on Friday, marking an eight-year low primarily due to concerns over AI competition and the departure of its CFO, despite reporting Q2 revenue of $6.62 billion, a 13% year-over-year increase, exceeding expectations.
- Analyst Downgrades Impact: Freedom Broker analyst downgraded Adobe from ‘Buy’ to ‘Hold’ and slashed the price target by over 50% to $250, citing a shift in growth quality and management's trade-off of near-term subscription revenue for customer acquisition, indicating weakened market confidence in Adobe's future.
- Chewy Faces Challenges: Chewy (CHWY) shares slid to a fresh 52-week low of $18.22 on Friday; despite reporting revenue and earnings growth in Q1, management warned of a challenging consumer pet environment, prompting analysts to cut price targets, with Goldman Sachs lowering it to $34 while maintaining a ‘Buy’ rating.
- Boston Scientific Stock Drop: Boston Scientific (BSX) shares fell to an annual low of $45.99 on Friday after receiving multiple price target cuts, with Piper Sandler lowering its target to $65, highlighting challenges from deceleration in key drivers and a more conservative outlook for 2027 growth estimates.
See More
Boston Scientific Stock Price Decline Analysis
- Poor Stock Performance: Boston Scientific (BSX) shares have fallen over 50% year-to-date, reflecting market disappointment with its growth expectations, particularly as management has repeatedly lowered guidance, undermining investor confidence.
- Guidance Downgrade: The management has revised its 2026 organic revenue growth forecast down to between 6.5% and 8%, and has indicated flat revenue growth for Q2 and Q3, raising concerns about the company's long-term investment appeal amid declining procedure usage.
- Analyst Optimism: Despite the bearish market sentiment, 27 out of 31 analysts still rate the stock as a buy, with a consensus price target of $78 per share, indicating a potential upside of 65%, which reflects analysts' confidence in the company's recovery potential.
- Valuation Challenges: Boston Scientific currently trades at a mid-teen forward valuation, comparable to other medical device firms like Abbott and Medtronic, and achieving a premium valuation will likely require a faster-than-expected recovery in growth, which appears challenging in the current market environment.
See More
Boston Scientific Shares Plunge Over 50% Amid Guidance Cuts
- Significant Stock Decline: Boston Scientific (NYSE: BSX) shares have plummeted over 50% year-to-date, primarily due to the company's ongoing downward revisions of its full-year 2026 guidance, which has severely undermined investor confidence and elicited a negative market response.
- Performance Guidance Adjustments: Management initially projected organic sales growth of 10% to 11% in February, but after reporting a 19.5% growth for 2025, investor reactions were poor, leading to further reductions in April and May, with 2026 organic revenue guidance now set between 6.5% and 8%.
- Analyst Sentiment Remains Positive: Despite the bearish market sentiment, 27 out of 31 analysts covering the stock still rate it as a buy, with a consensus price target of $78 per share, indicating a potential upside of 65%, reflecting analysts' confidence in the company's recovery prospects.
- Valuation Challenges Ahead: Boston Scientific currently trades at a forward valuation in the mid-teens, comparable to other medical device firms like Abbott and Medtronic, and achieving a premium valuation will likely require a faster-than-expected recovery in growth, which remains uncertain pending upcoming Q2 results and guidance.
See More
Boston Scientific Stock Decline Analysis
- Guidance Downgrade: Boston Scientific has lowered its organic revenue growth forecast for 2026 from 10%-11% to 6.5%-8%, resulting in a more than 50% decline in stock price this year, reflecting market pessimism about its future growth prospects.
- Analyst Rating Discrepancy: Despite a bearish shift in analyst sentiment, 27 out of 31 analysts still rate the stock as a buy, indicating optimism about potential recovery, with a consensus price target of $78 per share representing a 65% upside.
- Market Reaction Lag: Concerns over declining usage of the Watchman heart implant suggest that revenue may remain flat in Q2 and Q3, making it challenging for the stock to recover in the short term, prompting investors to proceed with caution.
- Cautious Investment Advice: While the attractive price target for Boston Scientific may entice investors, its current valuation aligns with other medical device companies, necessitating a careful assessment of potential risks versus rewards before making investment decisions.
See More
SpaceX Sets Record with $75 Billion IPO, Aiming for 25-30% Opening Pop
- Historic IPO: SpaceX is conducting a record-breaking IPO today, raising up to $75 billion, with expectations of a 25-30% opening pop, which could attract short-term investors and potentially destabilize the company's shareholder base.
- Market Reaction: Oil prices have dropped over 3% to below $85 per barrel due to optimism surrounding a potential peace deal between the U.S. and Iran, indicating market sentiment ahead of next week's G7 Summit.
- Executive Changes: Adobe announced that CFO Dan Durn is leaving to join Marvell; despite beating earnings expectations, Adobe's stock fell 7%, reflecting market concerns about slowing growth.
- Analyst Rating Changes: Citi upgraded AMD from hold to buy, anticipating that Meta will significantly increase its purchases of AMD chips, indicating AMD's strengthening position in the graphics processing unit market as a legitimate competitor to Nvidia.
See More
Elfun Trusts Q1 2026 Investment Moves Revealed
- Portfolio Adjustment: Elfun Trusts exited three stocks in Q1 2026, notably selling all 707,792 shares of Abbott Laboratories, which impacted the portfolio by -1.97%, indicating a cautious stance towards the healthcare sector.
- New Stock Additions: The fund added 1,148,700 shares of Boston Scientific, valued at approximately $72.08 million, representing 1.75% of the portfolio, reflecting optimism in the medical device industry.
- Key Position Increases: Elfun Trusts increased its stake in S&P Global by 47,560 shares, bringing total holdings to 222,549 shares, a 27.18% increase, demonstrating confidence in financial information services.
- Reduction Strategy: The fund reduced positions in 18 stocks, notably cutting 169,600 shares of Emerson Electric, a 25.49% decrease, reflecting a reassessment of the industry's outlook.
See More
